AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

"The move higher in Tesla shares bore no relation whatsoever to the company's financial performance in the quarter," JPMorgan ...

Good morning and thank you for standing by. Welcome to Booz Allen Hamilton’s Earnings Call covering Third Quarter Fiscal Year 2025 Results. [Operator Instructions] I’d now like to turn the call over ...

Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 11:53 am Looking ...

LYB remained sharply focused on executing its three-pillar strategyGenerated $3.8 billion of cash from operating activities with 90% cash ...

Kayne Anderson BDC, Inc. (NYSE: KBDC) (“KBDC”), a business development company externally managed by its investment adviser, ...

Presentation Kristie Waugh, Senior Vice President, Investor Relations at Raymond James Good evening, and welcome to Raymond James Financial's Fiscal 2025 First Quarter Earnings Call. This call is ...

Tech stocks dominated the list of biggest gainers after President Trump unveiled The Stargate Project, a new company formed ...

Infosys Share Price: Infosys shares fell nearly 5% after its Q3 results showed an 11% YoY net profit growth, reaching Rs 6,806 crore, and revenue increasing 8% YoY to Rs 41,764 crore. Despite revising ...

Wipro is likely to have a subdued third quarter with constant currency revenue expected to be declining and may well be the weakest among the peers. Agencies The estimates by Nomura, JM Financial, ...

The company's income statement breaks down its revenue, expenses, and earnings per share. Its P/E ratio is above average, which means people are willing to spend a high amount for each dollar of ...